A recent phase II trial, KEYLYNK-009, explored the efficacy of a maintenance strategy involving a checkpoint blockade and a PARP inhibitor for patients with triple-negative breast cancer (TNBC). Unfortunately, the results indicated that this approach did not improve survival outcomes for unselected patients with TNBC. Despite the disappointing findings, the trial did demonstrate a good
0 Comments
In a recent development, the governments of the United Kingdom and the United States have jointly imposed sanctions on two Russian hackers. The individuals in question, Andrey Stanislavovich Korinets and Ruslan Aleksandrovich Peretyatko, were found to be affiliated with a cyber unit of the FSB, known as the “Star Blizzard” group. This group has been
0 Comments
A recent randomized trial has revealed that low-dose naltrexone does not provide any additional pain relief compared to a placebo in patients with fibromyalgia. This is a significant setback for the hopes that this opioid receptor antagonist could be an effective treatment for a condition that has thus far been difficult to manage. The trial,
0 Comments